Novel mutations of the thyroid peroxidase gene in patients with permanent congenital hypothyroidism
Related Experiment Video
Updated: Oct 7, 2026

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model
Published on: March 17, 2023
P Ambrugger1, I Stoeva, H Biebermann
1Otto Heubner Zentrum für Kinder- und Jugendmedizin, Pädiatrische Endokrinologie, CVK, Humboldt University, Berlin, Germany.
Objective:
It is suggested that iodide organification defects account for 10% of all cases with congenital hypothyroidism (CH). One candidate gene for these defects is the thyroid peroxidase (TPO) gene.
Design:
Exons 2, 8-10 and 14 of the TPO gene were examined in 30 patients with permanent CH without a family history of CH. This group was characterized by the presence of an orthotopic thyroid gland and elevated TSH levels.
Methods:
The mutational screening was performed by single-strand conformational polymorphism followed by sequence analysis of fragments with abnormal migration patterns and by restriction enzyme analysis.
Results:
In four patients we were able to identify mutations on both alleles which have not been described so far. One patient was a carrier of a new homozygous point mutation in exon 9 resulting in an exchange from Leu to Pro at codon 458. Another patient was found to be compound heterozygous for two mutations, a 20 bp duplication in exon 2 and a new mutation in exon 9 (Arg491His). Two brothers of consanguineous parents showed a homozygous T deletion in exon 14 at position 2512.
Conclusions:
Our findings confirm the genetic heterogeneity of TPO defects and support the suggested prevalence of organification defects.
Related Concept Videos
Hypothyroidism II: Pathophysiology
Hyperthyroidism II: Pathophysiology
Pleiotropy
Hyperthyroidism I: Introduction
Synthesis and Regulation of Thyroid Hormones
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The iodine is then...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase